Overview This program is utilising molecular genetic techniques to improve the diagnosis and risk classification of childhood cancers including leukaemia and neuroblastoma. Major areas within the Program include molecular detection of residual disease following chemotherapy and the use of functional genomics and high-throughput screening strategies to detect novel molecular targets and relevant inhibitors.
